{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:22:16Z","timestamp":1786980136633,"version":"build-2736575974"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T00:00:00Z","timestamp":1597622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T00:00:00Z","timestamp":1597622400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The novel Coronavirus disease-19 (COVID-19) pandemic has posed several challenges for neuromuscular disorder (NMD) patients. The risk of a severe course of SARS-CoV-2 infection is increased in all but the mildest forms of NMDs. High-risk conditions include reduced airway clearance due to oropharyngeal weakness and risk of worsening with fever, fasting or infection Isolation requirements may have an impact on treatment regimens administered in hospital settings, such as nusinersen, glucosidase alfa, intravenous immunoglobulin, and rituximab infusions. In addition, specific drugs for SARS-CoV2 infection under investigation impair neuromuscular function significantly; chloroquine and azithromycin are not recommended in myasthenia gravis without available ventilatory support and prolonged prone positioning may influence options for treatment. Other therapeutics may affect specific NMDs (metabolic, mitochondrial, myotonic diseases) and experimental approaches for Coronavirus disease 2019 may be offered \u201ccompassionately\u201d only after consulting the patient\u2019s NMD specialist. In parallel, the reorganization of hospital and outpatient services may change the management of non-infected NMD patients and their caregivers, favouring at-distance approaches. However, the literature on the validation of telehealth in this subgroup of patients is scant. Thus, as the first wave of the pandemic is progressing, clinicians and researchers should address these crucial open issues to ensure adequate caring for NMD patients. This manuscript summarizes available evidence so far and provides guidance for both general neurologists and NMD specialists dealing with NMD patients in the time of COVID-19.<\/jats:p>","DOI":"10.1007\/s00415-020-10149-2","type":"journal-article","created":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T06:03:10Z","timestamp":1597644190000},"page":"1580-1591","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Management of patients with neuromuscular disorders at the time of the SARS-CoV-2 pandemic"],"prefix":"10.1007","volume":"268","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7989-585X","authenticated-orcid":false,"given":"Gianluca","family":"Costamagna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0797-8282","authenticated-orcid":false,"given":"Elena","family":"Abati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nereo","family":"Bresolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1383-5248","authenticated-orcid":false,"given":"Giacomo Pietro","family":"Comi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5425-969X","authenticated-orcid":false,"given":"Stefania","family":"Corti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,17]]},"reference":[{"key":"10149_CR1","doi-asserted-by":"publisher","unstructured":"Zhang Q, Cheng S, Cheng Q (2020) Experience summary of a COVID-19 designated community hospital and its operation model. Panminerva Med. https:\/\/doi.org\/10.23736\/S0031-0808.20.03908-7","DOI":"10.23736\/S0031-0808.20.03908-7"},{"key":"10149_CR2","doi-asserted-by":"publisher","unstructured":"Waldman G, Mayeux R, Claassen J, Agarwal S, Willey J, Anderson E, et al. (2020) Preparing a neurology department for SARS-CoV-2 (COVID-19): early experiences at Columbia University Irving Medical Center and the New York Presbyterian Hospital in New York City. Neurology 94(20):886\u2013891. https:\/\/doi.org\/10.1212\/WNL.0000000000009519","DOI":"10.1212\/WNL.0000000000009519"},{"key":"10149_CR3","doi-asserted-by":"publisher","unstructured":"Peters AW, Chawla KS, Turnbull ZA (2020) Transforming ORs into ICUs. N Engl J Med 382(19):e52. https:\/\/doi.org\/10.1056\/NEJMc2010853","DOI":"10.1056\/NEJMc2010853"},{"key":"10149_CR4","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1001\/jama.2020.4031","volume":"323","author":"G Grasselli","year":"2020","unstructured":"Grasselli G, Pesenti A, Cecconi M (2020) Critical care utilization for the COVID-19 outbreak in Lombardy, Italy: early experience and forecast during an emergency response. JAMA 323:1545\u20131546","journal-title":"JAMA"},{"key":"10149_CR5","unstructured":"Filippi M (2020) Invited commentary: being a neurologist in the COVID-19 era: an experience from Northern Italy. Neurology Blogs. https:\/\/blogs.neurology.org\/global\/invited-commentary-being-a-neurologist-in-the-covid-19-era-an-experience-from-northern-italy\/. Accessed 28 Apr 2020"},{"key":"10149_CR6","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000009566","author":"AC Guidon","year":"2020","unstructured":"Guidon AC, Amato AA (2020) COVID-19 and neuromuscular disorders. Neurology. https:\/\/doi.org\/10.1212\/WNL.0000000000009566","journal-title":"Neurology"},{"key":"10149_CR7","unstructured":"World Health Organization (2020) Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected: interim guidance. https:\/\/apps-who-int.pros.lib.unimi.it:2050\/iris\/handle\/10665\/330854. Accessed 26 Apr 2020"},{"key":"10149_CR8","unstructured":"World Muscle Society (2020) Covid-19 and people with neuromuscular disorders: World Muscle Society position and advice. https:\/\/www.worldmusclesociety.org\/news\/view\/150"},{"key":"10149_CR9","unstructured":"Muscular Distrophy Canada (2020) COVID-19 and neuromuscular patients. https:\/\/neuromuscularnetwork.ca\/news\/covid-19-and-neuromuscular-patients-la-covid-19-et-les-patients-neuromusculaires\/"},{"key":"10149_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-015-0264-3","author":"RS Scalco","year":"2015","unstructured":"Scalco RS, Gardiner AR, Pitceathly RD, Zanoteli E, Becker J, Holton JL et al (2015) Rhabdomyolysis: a genetic perspective. Orphanet J Rare Dis. https:\/\/doi.org\/10.1186\/s13023-015-0264-3","journal-title":"Orphanet J Rare Dis"},{"key":"10149_CR11","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.semarthrit.2016.03.001","volume":"46","author":"RM Joseph","year":"2016","unstructured":"Joseph RM, Hunter AL, Ray DW, Dixon WG (2016) Systemic glucocorticoid therapy and adrenal insufficiency in adults: a systematic review. Semin Arthritis Rheum 46:133\u2013141","journal-title":"Semin Arthritis Rheum"},{"key":"10149_CR12","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1016\/S2468-2667(20)30076-1","volume":"5","author":"R Armitage","year":"2020","unstructured":"Armitage R, Nellums LB (2020) The COVID-19 response must be disability inclusive. Lancet Public Health 5:e257","journal-title":"Lancet Public Health"},{"key":"10149_CR13","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1056\/NEJMc2011599","volume":"382","author":"S Fagiuoli","year":"2020","unstructured":"Fagiuoli S, Lorini FL, Remuzzi G (2020) Adaptations and lessons in the province of Bergamo. N Engl J Med 382:e71","journal-title":"N Engl J Med"},{"key":"10149_CR14","doi-asserted-by":"crossref","first-page":"718","DOI":"10.3201\/eid0906.030283","volume":"9","author":"S-J Twu","year":"2003","unstructured":"Twu S-J, Chen T-J, Chen C-J, Olsen SJ, Lee L-T, Fisk T et al (2003) Control measures for severe acute respiratory syndrome (SARS) in Taiwan. Emerg Infect Dis 9:718\u2013720","journal-title":"Emerg Infect Dis"},{"key":"10149_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.04.003","author":"F Pulvirenti","year":"2020","unstructured":"Pulvirenti F, Cinetto F, Milito C, Bonanni L, Pesce AM, Leodori G et al (2020) Health-related quality of life in common variable immunodeficiency Italian patients switched to remote assistance during the COVID-19 pandemic. J Allergy Clin Immunol. https:\/\/doi.org\/10.1016\/j.jaip.2020.04.003","journal-title":"J Allergy Clin Immunol"},{"key":"10149_CR16","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.1127","author":"L Mao","year":"2019","unstructured":"Mao L, Jin H, Wang M, Hu Y, Chen S, He Q et al (2019) Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. https:\/\/doi.org\/10.1001\/jamaneurol.2020.1127","journal-title":"JAMA Neurol"},{"key":"10149_CR17","doi-asserted-by":"publisher","unstructured":"Toscano G, Palmerini F, Ravaglia S, Ruiz L, Invernizzi P, Cuzzoni MG, et al. (2020) Guillain\u2013Barr\u00e9 syndrome associated with SARS-CoV-2. N Engl J Med 382(26):2574\u20132576. https:\/\/doi.org\/10.1056\/NEJMc2009191","DOI":"10.1056\/NEJMc2009191"},{"key":"10149_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30109-5","author":"H Zhao","year":"2020","unstructured":"Zhao H, Shen D, Zhou H, Liu J, Chen S (2020) Guillain-Barr\u00e9 syndrome associated with SARS-CoV-2 infection: causality or coincidence? Lancet Neurol. https:\/\/doi.org\/10.1016\/S1474-4422(20)30109-5","journal-title":"Lancet Neurol"},{"key":"10149_CR19","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/archneur.61.11.1669","volume":"61","author":"L-K Tsai","year":"2004","unstructured":"Tsai L-K, Hsieh S-T, Chao C-C, Chen Y-C, Lin Y-H, Chang S-C et al (2004) Neuromuscular disorders in severe acute respiratory syndrome. Arch Neurol 61:1669\u20131673","journal-title":"Arch Neurol"},{"key":"10149_CR20","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000009677","author":"SN Grossman","year":"2020","unstructured":"Grossman SN, Han SC, Balcer LJ, Kurzweil A, Weinberg H, Galetta SL et al (2020) Rapid implementation of virtual neurology in response to the COVID-19 pandemic. Neurology. https:\/\/doi.org\/10.1212\/WNL.0000000000009677","journal-title":"Neurology"},{"key":"10149_CR21","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/mus.26115","volume":"58","author":"IM Howard","year":"2018","unstructured":"Howard IM, Kaufman MS (2018) Telehealth applications for outpatients with neuromuscular or musculoskeletal disorders. Muscle Nerve 58:475\u2013485","journal-title":"Muscle Nerve"},{"key":"10149_CR22","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1212\/WNL.0000000000008708","volume":"94","author":"JM Hatcher-Martin","year":"2020","unstructured":"Hatcher-Martin JM, Adams JL, Anderson ER, Bove R, Burrus TM, Chehrenama M et al (2020) Telemedicine in neurology. Neurology 94:30","journal-title":"Neurology"},{"key":"10149_CR23","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1089\/tmj.2013.0217","volume":"20","author":"LE Davis","year":"2014","unstructured":"Davis LE, Coleman J, Harnar J, King MK (2014) Teleneurology: successful delivery of chronic neurologic care to 354 patients living remotely in a rural state. Telemed J E Health 20:473\u2013477","journal-title":"Telemed J E Health"},{"key":"10149_CR24","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1080\/21678421.2017.1338298","volume":"18","author":"A Geronimo","year":"2017","unstructured":"Geronimo A, Wright C, Morris A, Walsh S, Snyder B, Simmons Z (2017) Incorporation of telehealth into a multidisciplinary ALS Clinic: feasibility and acceptability. Amyotroph Lateral Scler Frontotemporal Degener 18:555\u2013561","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"10149_CR25","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/mus.26170","volume":"59","author":"MT Pulley","year":"2019","unstructured":"Pulley MT, Brittain R, Hodges W, Frazier C, Miller L, Matyjasik-Liggett M et al (2019) Multidisciplinary amyotrophic lateral sclerosis telemedicine care: the store and forward method. Muscle Nerve 59:34\u201339","journal-title":"Muscle Nerve"},{"key":"10149_CR26","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/21678421.2017.1392577","volume":"19","author":"M Van De Rijn","year":"2018","unstructured":"Van De Rijn M, Paganoni S, Levine-Weinberg M, Campbell K, Swartz Ellrodt A, Estrada J et al (2018) Experience with telemedicine in a multi-disciplinary ALS clinic. Amyotroph Lateral Scler Frontotemporal Degener 19:143\u2013148","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"10149_CR27","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1080\/21678421.2017.1313867","volume":"18","author":"SM Selkirk","year":"2017","unstructured":"Selkirk SM, Washington MO, McClellan F, Flynn B, Seton JM, Strozewski R (2017) Delivering tertiary centre specialty care to ALS patients via telemedicine: a retrospective cohort analysis. Amyotroph Lateral Scler Frontotemporal Degener 18:324\u2013332","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"10149_CR28","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3109\/21678421.2016.1165255","volume":"17","author":"EV Hobson","year":"2016","unstructured":"Hobson EV, Baird WO, Cooper CL, Mawson S, Shaw PJ, Mcdermott CJ (2016) Using technology to improve access to specialist care in amyotrophic lateral sclerosis: a systematic review. Amyotroph Lateral Scler Frontotemporal Degener 17:313\u2013324","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"10149_CR29","doi-asserted-by":"publisher","DOI":"10.1258\/1357633001934122","author":"J Craig","year":"2000","unstructured":"Craig J, Chua R, Russell C, Patterson V, Wootton R (2000) The cost-effectiveness of teleneurology consultations for patients admitted to hospitals without neurologists on site. 1: a retrospective comparison of the case-mix and management at two rural hospitals. J Telemed Telecare. https:\/\/doi.org\/10.1258\/1357633001934122","journal-title":"J Telemed Telecare"},{"key":"10149_CR30","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.dhjo.2017.09.003","volume":"11","author":"S Portaro","year":"2018","unstructured":"Portaro S, Calabr\u00f2 RS, Bramanti P, Silvestri G, Torrisi M, Conti-Nibali V et al (2018) Telemedicine for Facio-Scapulo-Humeral Muscular Dystrophy: a multidisciplinary approach to improve quality of life and reduce hospitalization rate? Disabil Health J 11:306\u2013309","journal-title":"Disabil Health J"},{"key":"10149_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.01050","author":"AM Wilson","year":"2019","unstructured":"Wilson AM, Ong MK, Saliba D, Jamal NI (2019) The veterans affairs neuropathy scale: a reliable remote polyneuropathy exam. Front Neurol. https:\/\/doi.org\/10.3389\/fneur.2019.01050","journal-title":"Front Neurol"},{"key":"10149_CR32","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00415-019-09553-0","volume":"267","author":"AM Wilson","year":"2020","unstructured":"Wilson AM, Jamal NI, Cheng EM, Inkelas M, Saliba D, Hanssen A et al (2020) Teleneurology clinics for polyneuropathy: a pilot study. J Neurol 267:479\u2013490","journal-title":"J Neurol"},{"key":"10149_CR33","doi-asserted-by":"crossref","unstructured":"Khan F, Amatya B, Kesselring J, Galea M (2015) Telerehabilitation for persons with multiple sclerosis. Cochrane Database Syst Rev CD010508","DOI":"10.1002\/14651858.CD010508.pub2"},{"key":"10149_CR34","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1682\/JRRD.2014.10.0239","volume":"52","author":"CE Levy","year":"2015","unstructured":"Levy CE, Silverman E, Jia H, Geiss M, Omura D (2015) Effects of physical therapy delivery via home video telerehabilitation on functional and health-related quality of life outcomes. J Rehabil Res Dev 52:361\u2013370","journal-title":"J Rehabil Res Dev"},{"key":"10149_CR35","doi-asserted-by":"crossref","first-page":"e002670","DOI":"10.1136\/bmjgh-2020-002670","volume":"5","author":"JP Bettger","year":"2020","unstructured":"Bettger JP, Thoumi A, Marquevich V, Groote WD, Battistella LR, Imamura M et al (2020) COVID-19: maintaining essential rehabilitation services across the care continuum. BMJ Global Health 5:e002670","journal-title":"BMJ Global Health"},{"key":"10149_CR36","doi-asserted-by":"publisher","DOI":"10.1097\/MRR.0000000000000418","author":"V Prada","year":"2020","unstructured":"Prada V, Bellone E, Schenone A, Grandis M (2020) The suspected SARS-Cov-2 infection in a Charcot-Marie-Tooth patient undergoing postsurgical rehabilitation: the value of telerehabilitation for evaluation and continuing treatment. Int J Rehabil Res. https:\/\/doi.org\/10.1097\/MRR.0000000000000418(Publish Ahead of Print)","journal-title":"Int J Rehabil Res"},{"key":"10149_CR37","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-10063-7","author":"M Garibaldi","year":"2020","unstructured":"Garibaldi M, Siciliano G, Antonini G (2020) Telemedicine for neuromuscular disorders during the COVID-19 outbreak. J Neurol. https:\/\/doi.org\/10.1007\/s00415-020-10063-7","journal-title":"J Neurol"},{"key":"10149_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2020.116803","author":"S Jacob","year":"2020","unstructured":"Jacob S, Muppidi S, Guidon A, Guptill J, Hehir M, Howard JF et al (2020) Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic. J Neurol Sci. https:\/\/doi.org\/10.1016\/j.jns.2020.116803","journal-title":"J Neurol Sci"},{"key":"10149_CR39","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","volume":"87","author":"DB Sanders","year":"2016","unstructured":"Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I et al (2016) International consensus guidance for management of myasthenia gravis: executive summary. Neurology 87:419\u2013425","journal-title":"Neurology"},{"key":"10149_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.03052","author":"KL Gable","year":"2020","unstructured":"Gable KL, Guptill JT (2020) Antagonism of the neonatal Fc receptor as an emerging treatment for myasthenia gravis. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2019.03052","journal-title":"Front Immunol"},{"key":"10149_CR41","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa248","author":"C Qin","year":"2020","unstructured":"Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y et al (2020) Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis 71(15):762\u2013768. https:\/\/doi.org\/10.1093\/cid\/ciaa248","journal-title":"Clin Infect Dis"},{"key":"10149_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2020.04.002","author":"M Aruru","year":"2020","unstructured":"Aruru M, Truong H-A, Clark S (2020) Pharmacy emergency preparedness and response (PEPR): a proposed framework for expanding pharmacy professionals\u2019 roles and contributions to emergency preparedness and response during the COVID-19 pandemic and beyond. Res Soc Adm Pharm. https:\/\/doi.org\/10.1016\/j.sapharm.2020.04.002","journal-title":"Res Soc Adm Pharm"},{"key":"10149_CR43","unstructured":"Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019Anesth\u00e9sie et de R\u00e9animation. Comit\u00e9 \u00e9thique: \u00e0 propos des d\u00e9cisions m\u00e9dicales d\u2019admission des patients en unit\u00e9 de soins critiques en context pand\u00e9mique\u202f: quelques rep\u00e8res \u00e9thiques. Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019Anesth\u00e9sie et de R\u00e9animation. https:\/\/sfar.org\/download\/comite-ethique-a-propos-des-decisions-medicales-dadmission-des-patients-en-unite-de-soins-critiques-en-context-pandemique-quelques-reperes-ethiques\/. Accessed 27 May 2020"},{"key":"10149_CR44","doi-asserted-by":"publisher","unstructured":"Vergano M, Bertolini G, Giannini A, Gristina G, Livigni S, Mistraletti G, et al. (2020) Clinical ethics recommendations for the allocation of intensive care treatments, in exceptional, resource-limited circumstances. Recenti Prog Med 111(4):207\u2013211. https:\/\/doi.org\/10.1701\/3347.33183","DOI":"10.1701\/3347.33183"},{"key":"10149_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurol.2020.04.004","author":"G Sol\u00e9","year":"2020","unstructured":"Sol\u00e9 G, Salort-Campana E, Pereon Y, Stojkovic T, Wahbi K, Cintas P et al (2020) Guidance for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases Network. Rev Neurol (Paris). https:\/\/doi.org\/10.1016\/j.neurol.2020.04.004","journal-title":"Rev Neurol (Paris)"},{"key":"10149_CR46","doi-asserted-by":"publisher","unstructured":"Anand P, Slama MCC, Kaku M, Ong C, Cervantes-Arslanian AM, Zhou L, et al. (2020) COVID-19 in patients with myasthenia gravis. Muscle Nerve 62(2):254\u2013258. https:\/\/doi.org\/10.1002\/mus.26918","DOI":"10.1002\/mus.26918"},{"key":"10149_CR47","doi-asserted-by":"crossref","first-page":"116888","DOI":"10.1016\/j.jns.2020.116888","volume":"414","author":"F Delly","year":"2020","unstructured":"Delly F, Syed MJ, Lisak RP, Zutshi D (2020) Myasthenic crisis in COVID-19. J Neurol Sci 414:116888","journal-title":"J Neurol Sci"},{"key":"10149_CR48","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.5394","author":"G Grasselli","year":"2020","unstructured":"Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A et al (2020) Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA. https:\/\/doi.org\/10.1001\/jama.2020.5394","journal-title":"JAMA"},{"key":"10149_CR49","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4326","author":"M Arentz","year":"2020","unstructured":"Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M et al (2020) Characteristics and outcomes of 21 critically Ill patients with COVID-19 in Washington State. JAMA. https:\/\/doi.org\/10.1001\/jama.2020.4326","journal-title":"JAMA"},{"key":"10149_CR50","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jama.2020.1585","volume":"323","author":"D Wang","year":"2020","unstructured":"Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J et al (2020) Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 323:1061\u20131069","journal-title":"JAMA"},{"key":"10149_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30079-5","author":"X Yang","year":"2020","unstructured":"Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H et al (2020) Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. https:\/\/doi.org\/10.1016\/S2213-2600(20)30079-5","journal-title":"Lancet Respir Med"},{"key":"10149_CR52","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395:497\u2013506","journal-title":"Lancet"},{"key":"10149_CR53","doi-asserted-by":"crossref","first-page":"389","DOI":"10.7326\/M13-2486","volume":"160","author":"YM Arabi","year":"2014","unstructured":"Arabi YM, Arifi AA, Balkhy HH, Najm H, Aldawood AS, Ghabashi A et al (2014) Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection. Ann Intern Med 160:389\u2013397","journal-title":"Ann Intern Med"},{"key":"10149_CR54","doi-asserted-by":"publisher","unstructured":"Hui DS, Chow BK, Lo T, Tsang OTY, Ko FW, Ng SS, et al. (2019) Exhaled air dispersion during high-flow nasal cannula therapy versus CPAP via different masks. Eur Respir J 53(4):1802339. https:\/\/doi.org\/10.1183\/13993003.02339-2018","DOI":"10.1183\/13993003.02339-2018"},{"key":"10149_CR55","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1378\/chest.14-1934","volume":"147","author":"DS Hui","year":"2015","unstructured":"Hui DS, Chow BK, Lo T, Ng SS, Ko FW, Gin T et al (2015) Exhaled air dispersion during noninvasive ventilation via helmets and a total facemask. Chest 147:1336\u20131343","journal-title":"Chest"},{"key":"10149_CR56","first-page":"15","volume":"79","author":"F Racca","year":"2013","unstructured":"Racca F, Mongini T, Wolfler A, Vianello A, Cutrera R, Sorbo LD et al (2013) Recommendations for anesthesia and perioperative management of patients with neuromuscular disorders. Minerva Anestesiol 79:15","journal-title":"Minerva Anestesiol"},{"key":"10149_CR57","unstructured":"Anesthesia and perioperative medical management of children with spinal muscular atrophy\u2014GRAHAM\u20142009\u2014Pediatric Anesthesia\u2014Wiley Online Library. https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1111\/j.1460\u20139592.2009.03055.x. Accessed 28 Apr 2020"},{"key":"10149_CR58","first-page":"617","volume":"71","author":"F Petrini","year":"2005","unstructured":"Petrini F, Accorsi A, Adrario E, Agr\u00f2 F, Amicucci G, Antonelli M et al (2005) Recommendations for airway control and difficult airway management. Minerva Anestesiol 71:617\u2013657","journal-title":"Minerva Anestesiol"},{"key":"10149_CR59","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.nmd.2004.10.017","volume":"15","author":"W Klingler","year":"2005","unstructured":"Klingler W, Lehmann-Horn F, Jurkat-Rott K (2005) Complications of anaesthesia in neuromuscular disorders. Neuromuscul Disord 15:195\u2013206","journal-title":"Neuromuscul Disord"},{"key":"10149_CR60","doi-asserted-by":"publisher","unstructured":"Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Sevestre J, et al. (2020) Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study. Travel Med Infect Dis 34:101663. https:\/\/doi.org\/10.1016\/j.tmaid.2020.101663","DOI":"10.1016\/j.tmaid.2020.101663"},{"key":"10149_CR61","doi-asserted-by":"crossref","unstructured":"Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. (2020) Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 105949","DOI":"10.1016\/j.ijantimicag.2020.105949"},{"key":"10149_CR62","doi-asserted-by":"crossref","first-page":"e208857","DOI":"10.1001\/jamanetworkopen.2020.8857","volume":"3","author":"MGS Borba","year":"2020","unstructured":"Borba MGS, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, Brito M et al (2020) Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. JAMA Netw Open 3:e208857\u2013e208857","journal-title":"JAMA Netw Open"},{"key":"10149_CR63","first-page":"795","volume":"25","author":"JA Silva","year":"2007","unstructured":"Silva JA, Silva MB, Skare TL (2007) Chloroquine and QTc interval. Clin Exp Rheumatol 25:795","journal-title":"Clin Exp Rheumatol"},{"key":"10149_CR64","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1212\/WNL.51.4.1226","volume":"51","author":"M Wasay","year":"1998","unstructured":"Wasay M, Wolfe GI, Herrold JM, Burns DK, Barohn RJ (1998) Chloroquine myopathy and neuropathy with elevated CSF protein. Neurology 51:1226\u20131227","journal-title":"Neurology"},{"key":"10149_CR65","first-page":"849","volume":"67","author":"O Varan","year":"2015","unstructured":"Varan O, Kucuk H, Tufan A (2015) Myasthenia gravis due to hydroxychloroquine. Reumatismo 67:849","journal-title":"Reumatismo"},{"key":"10149_CR66","doi-asserted-by":"publisher","unstructured":"Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. (2020) Compassionate use of remdesivir for patients with severe covid-19. N Engl J Med 382(24):2327\u20132336. https:\/\/doi.org\/10.1056\/NEJMoa2007016","DOI":"10.1056\/NEJMoa2007016"},{"key":"10149_CR67","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","volume":"381","author":"S Mulangu","year":"2019","unstructured":"Mulangu S, Dodd LE, Davey RT, Tshiani Mbaya O, Proschan M, Mukadi D et al (2019) A randomized, controlled trial of ebola virus disease therapeutics. N Engl J Med 381:2293\u20132303","journal-title":"N Engl J Med"},{"key":"10149_CR68","first-page":"4040","volume":"24","author":"F Diurno","year":"2020","unstructured":"Diurno F, Numis FG, Porta G, Cirillo F, Maddaluno S, Ragozzino A et al (2020) Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience. Eur Rev Med Pharmacol Sci 24:4040\u20134047","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10149_CR69","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1073\/pnas.78.6.3605","volume":"78","author":"DK Miller","year":"1981","unstructured":"Miller DK, Lenard J (1981) Antihistaminics, local anesthetics, and other amines as antiviral agents. PNAS 78:3605\u20133609","journal-title":"PNAS"},{"key":"10149_CR70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1743-422X-2-69","volume":"2","author":"MJ Vincent","year":"2005","unstructured":"Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG et al (2005) Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2:1\u201310","journal-title":"Virol J"},{"key":"10149_CR71","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.bbrc.2004.08.085","volume":"323","author":"E Keyaerts","year":"2004","unstructured":"Keyaerts E, Vijgen L, Maes P, Neyts J, Ranst MV (2004) In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun 323:264\u2013268","journal-title":"Biochem Biophys Res Commun"},{"key":"10149_CR72","first-page":"185","volume":"43","author":"Z Jie","year":"2020","unstructured":"Jie Z, He H, Xi H, Zhi Z (2020) Multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia. Expert Consens Chloroquine Phosphate Treat Novel Coronavirus Pneumonia 43:185\u2013188","journal-title":"Expert Consens Chloroquine Phosphate Treat Novel Coronavirus Pneumonia"},{"key":"10149_CR73","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","volume":"30","author":"M Wang","year":"2020","unstructured":"Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M et al (2020) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30:269\u2013271","journal-title":"Cell Res"},{"key":"10149_CR74","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5582\/bst.2020.01047","volume":"14","author":"J Gao","year":"2020","unstructured":"Gao J, Tian Z, Yang X (2020) Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. BioScience Trends 14:72\u201373","journal-title":"BioScience Trends"},{"key":"10149_CR75","doi-asserted-by":"publisher","unstructured":"Molina JM, Delaugerre C, Le Goff J, Mela-Lima B, Ponscarme D, Goldwirt L, et al. (2020) No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med Mal Infect 50(4):384. https:\/\/doi.org\/10.1016\/j.medmal.2020.03.006","DOI":"10.1016\/j.medmal.2020.03.006"},{"key":"10149_CR76","unstructured":"Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. (2020) A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med"},{"key":"10149_CR77","unstructured":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial\u2014The Lancet. https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(20)31022-9\/fulltext#seccestitle150. Accessed 6 May 2020"},{"key":"10149_CR78","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.4049\/jimmunol.1801228","volume":"203","author":"D Haydar","year":"2019","unstructured":"Haydar D, Cory TJ, Birket SE, Murphy BS, Pennypacker KR, Sinai AP et al (2019) Azithromycin polarizes macrophages to an M2 phenotype via inhibition of the STAT1 and NF-\u03baB signaling pathways. J Immunol 203:1021\u20131030","journal-title":"J Immunol"},{"key":"10149_CR79","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.ijantimicag.2018.02.009","volume":"51","author":"K Kawamura","year":"2018","unstructured":"Kawamura K, Ichikado K, Takaki M, Eguchi Y, Anan K, Suga M (2018) Adjunctive therapy with azithromycin for moderate and severe acute respiratory distress syndrome: a retrospective, propensity score-matching analysis of prospectively collected data at a single center. Int J Antimicrob Agents 51:918\u2013924","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"10149_CR80","doi-asserted-by":"publisher","first-page":"102537","DOI":"10.1016\/j.autrev.2020.102537","volume":"16","author":"D McGonagle","year":"2020","unstructured":"McGonagle D, Sharif K, O\u2019Regan A, Bridgewood C (2020) The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev 19(6):102537. https:\/\/doi.org\/10.1016\/j.autrev.2020.102537","journal-title":"Autoimmun Rev"},{"key":"10149_CR81","doi-asserted-by":"publisher","unstructured":"Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J (2020) Tocilizumab treatment in COVID-19: a single center experience. J Med Virol 92(7):814\u2013818. https:\/\/doi.org\/10.1002\/jmv.25801","DOI":"10.1002\/jmv.25801"},{"key":"10149_CR82","doi-asserted-by":"crossref","unstructured":"Michot J-M, Albiges L, Chaput N, Saada V, Pommeret F, Griscelli F, et al. (2020) Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report. Ann Oncol","DOI":"10.1016\/j.annonc.2020.03.300"},{"key":"10149_CR83","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","volume":"16","author":"JF Howard","year":"2017","unstructured":"Howard JF, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I et al (2017) Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 16:976\u2013986","journal-title":"Lancet Neurol"},{"key":"10149_CR84","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/mus.26447","volume":"60","author":"S Muppidi","year":"2019","unstructured":"Muppidi S, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I et al (2019) Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle Nerve 60:14\u201324","journal-title":"Muscle Nerve"},{"key":"10149_CR85","doi-asserted-by":"publisher","unstructured":"Sapp JL, Alqarawi W, MacIntyre CJ, Tadros R, Steinberg C, Roberts JD, et al. (2020) Guidance on minimizing risk of drug-induced ventricular arrhythmia during treatment of COVID-19: a statement from the canadian heart rhythm society. Can J Cardiol 36(6):948\u2013951. https:\/\/doi.org\/10.1016\/j.cjca.2020.04.003","DOI":"10.1016\/j.cjca.2020.04.003"},{"key":"10149_CR86","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3988\/jcn.2013.9.3.186","volume":"9","author":"KM Park","year":"2013","unstructured":"Park KM, Shin KJ, Kim SE, Park J, Ha SY, Kim BJ (2013) Prolonged corrected QT interval in patients with myotonic dystrophy type 1. J Clin Neurol 9:186\u2013191","journal-title":"J Clin Neurol"},{"issue":"3 Pt 1","key":"10149_CR87","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/0002-9343(88)90300-2","volume":"84","author":"VP Purohit","year":"1988","unstructured":"Purohit VP (1988) Chloroquine neuromyotoxicity. Am J Med 84(3 Pt 1):568","journal-title":"Am J Med"},{"key":"10149_CR88","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1089\/108729103321655854","volume":"17","author":"JB Mah Ming","year":"2003","unstructured":"Mah Ming JB, Gill MJ (2003) Drug-induced rhabdomyolysis after concomitant use of clarithromycin, atorvastatin, and lopinavir\/ritonavir in a patient with HIV. AIDS Patient Care STDS 17:207\u2013210","journal-title":"AIDS Patient Care STDS"},{"key":"10149_CR89","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3851\/IMP1747","volume":"16","author":"CTMM de Kanter","year":"2011","unstructured":"de Kanter CTMM, Keuter M, van der Lee MJ, Koopmans PP, Burger DM (2011) Rhabdomyolysis in an HIV-infected patient with impaired renal function concomitantly treated with rosuvastatin and lopinavir\/ritonavir. Antivir Ther (Lond) 16:435\u2013437","journal-title":"Antivir Ther (Lond)"},{"key":"10149_CR90","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/mus.26689","volume":"60","author":"RR Gummi","year":"2019","unstructured":"Gummi RR, Kukulka NA, Deroche CB, Govindarajan R (2019) Factors associated with acute exacerbations of myasthenia gravis. Muscle Nerve 60:693\u2013699","journal-title":"Muscle Nerve"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-020-10149-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-020-10149-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-020-10149-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T17:42:49Z","timestamp":1696527769000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-020-10149-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,17]]},"references-count":90,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["10149"],"URL":"https:\/\/doi.org\/10.1007\/s00415-020-10149-2","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,17]]},"assertion":[{"value":"16 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declared that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}